Fig. 1: Preparation, characterization and safety of the AIBP vaccine.
a, Survival of B. pertussis cultured in S&S medium at a starting concentration of 6 × 107 CFU ml−1 with 0.1–0.5 mg ml−1 of ciprofloxacin or medium only; live bacteria were quantified by performing CFU counts on BG agar plates at 2 h, 4 h and 6 h. Data are the mean ± s.d. of biological replicates (n = 3). b, Female 6–8-week-old C57BL/6 mice were exposed to an aerosol of live B. pertussis or AIBP vaccine, and CFU were assessed in lungs and nasal tissue after 2 h, 24 h and 72 h. Data are the mean ± s.d. of biological replicates (n = 3 for each time point). c–e, Female 6–8-week-old C57BL/6 mice were immunized by aerosol administration of the AIBP vaccine (equivalent to a culture of 1 × 109 CFU ml−1) or were immunized intramuscularly with a wP vaccine (1/50 human dose), and the concentrations of TNF, IL-1β and IL-6 were quantified in serum after 4 h and 24 h (n = 4 for each time point) (c), the concentration of CRP was quantified in serum after 48 h (n = 5) (d) and the number of neutrophils in the spleen was quantified by flow cytometry after 24 h and 48 h (n = 5 for each time point) (e). f, Female 6–8-week-old C57BL/6 mice were exposed to an aerosol of live B. pertussis or AIBP vaccine, and after 24 h, the concentration of PT was quantified in the lung by ELISA (n = 5). Data in c–f are presented as the mean ± s.e.m. of biological replicates (n = 4 or 5) shown as individual symbols. Data were analysed by two-way ANOVA followed by Tukey’s test for multiple comparisons. P values are shown above data compared.
